Jody Baron and Gabi Fragiadakis discover why some people with chronic Hepatitis B are cured after they're taken off of ...
University of California, San Francisco researchers have identified a crucial immune mechanism involving CD4+ T cells that ...
FDA regulatory momentum includes priority review and breakthrough therapy designation for a potential first-in-class CHB ...
Fifteen years ago, doctors in Europe noticed a remarkable thing happening in people with chronic hepatitis B infections. When ...
Bepirovirsen demonstrated a statistically significant functional cure rate vs placebo in participants with baseline HBsAg less than or equal to 3000 IU/mL. Topline data were announced from two phase 3 ...
More than 75% of chronic hepatitis B diagnoses in the United States occur late — within 2 years before or after the onset of a liver complication — highlighting the need for improved screening to ...
An experimental GSK drug in development for treating chronic hepatitis B now has results from two pivotal studies showing the therapy brought levels of the virus low enough to allow the immune system ...
Chronic hepatitis B (CHB) affects more than 254 million people globally, with 1.2 million new infections occurring each year. 1 And while it has the potential to cause severe long-term liver problems ...
Hepatitis B virus infection remains one of the leading causes of liver disease, including cirrhosis and hepatocellular carcinoma. Despite widespread vaccination and antiviral treatments, millions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results